Navigation Links
D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
Date:5/6/2009

REHOVOT, Israel, May 6 /PRNewswire/ -- D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA. Recently, D-Pharm also obtained Scientific Advice from the European Medicines Agency (EMEA) on the development strategy for DP-b99 in Europe.

Prior to the IND submission D-Pharm successfully completed the program outlined at the pre-IND meeting held with the FDA in January 2008. The program included additional toxicity studies, a drug interaction study with rtPA, and an interaction study with warfarin in healthy volunteers, as well as scale-up and optimization of the DP-b99 manufacturing process.

The planned Phase III trial is a randomized, double blind, placebo-controlled study (study acronym MACSI: Membrane Activated Chelator Stroke Intervention). It is designed to compare the effect on ischemic stroke outcome between a placebo group and a group of patients treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. D-Pharm plans to enroll 770 moderate to severely affected ischemic stroke patients in over 100 clinical sites in North America, Europe, South Africa and Israel.

"I am especially pleased with this achievement since bringing DP-b99 from design to Phase III really reflects the company's ability to adapt and mature along with our lead product. I look forward to agreement on the SPA and commencing our Phase III trial with DP-b99 under IND" said Alex Kozak, PhD, CEO and President of D-Pharm.

Special Protocol Assessment (SPA) is an instrument of the FDA for evaluating protocols and reaching agreement with sponsors on the design of clinical trials that can be used for drug approval. In our case, it applies to a clinica
'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
2. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
3. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
4. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
5. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
6. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
7. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
8. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
9. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
10. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Alvarado Hospital unveiled its new facility ... & Joint Institute. The institute is entirely devoted ... surgery and joint replacement. The Spine & Joint ... experience-focused approach. For example, patients are encouraged to ... than patient gowns. "From the ...
(Date:7/29/2015)... LAKE FOREST, Calif. , July 29, ... ) ("Cryoport" or the "Company"), the leading ... the life sciences industry, serving markets including ... organizations, vaccine manufacturers, animal health, and reproductive ... completed the sale of common stock and warrants ...
(Date:7/29/2015)...  Ortho-Clinical Diagnostics, Inc. (OCD) today announced the presentation ... address a range of important tests for clinical labs ... The scientific posters will be delivered during the 2015 ... held July 26 - 30 in Atlanta, ... is emerging stronger than ever since becoming a stand-alone ...
Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
... DIEGO, Feb. 11, 2011 Conatus Pharmaceuticals Inc. today ... Preferred Stock private placement financing.  This financing was led ... and included participation by existing investors; Aberdare Ventures, Advent ... Roche Venture Fund.  Conatus will use the proceeds to ...
... LOS ANGELES, Feb. 11, 2011 Nationally-acclaimed researcher and ... speech at the 11th National Conference on Cancer Nursing ... potentially deadly infections they were supposed to prevent. ... needleless IV connector devices with silver coated or silver ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to ... commonly known as the “bionic eye,” researchers have determined the trial to be a ... patients facing or already affected by complete vision loss as a result of Retinitis ...
(Date:7/30/2015)... ... July 30, 2015 , ... According to Chicago ... find a complete removable denture acceptable. The demand for dental implants is rising ... less expensive, immediate loading techniques will have the ability to offer the patient ...
(Date:7/30/2015)... ... 2015 , ... When trying to gain weight, many people place a lot of focus on the different types ... to be consumed. However, another key component to successful weight gain is knowing when ... this, CB-1 Weight Gainer gives three tips on when to eat to gain weight. ...
(Date:7/30/2015)... ... ... PeopleKeys, a company with over 30 years of experience in behavioral analysis, ... the newest installment in their popular DISC for the Real World series, will air ... webinar is intended for people interested in training others to use DISC behavioral analysis ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2
... WASHINGTON, April 8, 2008 The following is a,statement ... Governor Ted Strickland and Ohio legislators have abandoned ... their underhanded actions today to,raid funds from the Ohio ... to come more Ohio children will become addicted to,tobacco, ...
... Important to Protect Animal, Human Health, WASHINGTON, ... today launched its newly designed "Keeping Animals Healthy",website ... important,role of public policy in providing animal medicines ... are becoming more aware of the relationship between ...
... Filed in ... ... KV Pharmaceutical,Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical,company that ... pharmaceutical,products, announced today that it has reached a comprehensive settlement,agreement ...
... Clinical Trial Results on Preoperative Chemotherapy in Early Breast ... no better than six cycles in women with early ... according to data from a randomized controlled trial. Additionally, ... cycles of one drug combination did not benefit from ...
... of the main obstacles towards progress in the developing ... that have not been seriously addressed by the public ... new book, Forgotten People, Forgotten Diseases, published by ASM ... the world have too long been ignored. Parasitic ...
... Ultravist(R) are part of Amerinet,s Portfolio of ... Contracted ... HealthCare,Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that,the ... to make,Magnevist(R) (gadopentetate dimeglumine) injection and Ultravist(R),(iopromide) injection available to ...
Cached Medicine News:Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 3Health News:Other highlights in the April 8 JNCI 2Health News:Other highlights in the April 8 JNCI 3Health News:Other highlights in the April 8 JNCI 4Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 2Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 3Health News:Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement 4
... The new Primus PDQ Plus for the determination ... and accurate results. The PDQ Plus is a ... on-line barcode reading for the ultimate in safety ... affinity which is well known to be interference-free ...
Micromat II Hemoglobin A1c instrument is an easy-to-use, accurate and precise instrument with an requirement of only 10 L of capillary or venous sample....
... Cascade M-4 is a manual hemostasis ... routine clotting assays - PTs, aPTTs, ... for easy, inexpensive, low-volume testing, this ... big on features, offering time and ...
... a fully automated, benchtop coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
Medicine Products: